A Phase 3 interventional study of Aerobic Exercise and Counseling in Nicotine Dependence, sponsored by Jasper A. Smits. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Jasper A. Smits · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing Nicotine Patch in Tobacco Use Disorder — 4 open to participants now, 5 under way, 2 of them phase 3. Nicotine Patch · Tobacco Use Disorder.
Among the 42 studies testing Nicotine Patch in Tobacco Use Disorder, this one is the 13th largest by planned enrollment, is one of 2 that started in 2023, is one of 5 in phase 3, and was the 41st registered.
1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.
Browse Tobacco Use Disorder studies →4 of the 42 studies testing Nicotine Patch in Tobacco Use Disorder are open now, in 4 countries. Recruiting first, the newest first:
Henan Provincial People's Hospital · Sites in China
Ages 18–75 · Men only
University of Oklahoma · Sites in United States
Ages 21–60 · Healthy volunteers
University of Southern California · Sites in Uganda, Zambia
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Nicotine Patch: first FDA approval 1991 (NICODERM CQ). What it is approved for, and how studies give it, is on its page →
Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 8 · Phase 4 14
First in 1999; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 90 across 893 interventional studies indexed under Tobacco Use Disorder.
Median enrollment 135 across the 42 interventional studies. Of the 35 that completed or were terminated, 21 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 42 have an industry lead sponsor. The 10 most frequent:
Jasper A. Smits is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Jasper A. Smits has 5 studies filed under Tobacco Use Disorder — fewer than ten, so there is no comparison to draw.
3 of the studies testing Nicotine Patch in Tobacco Use Disorder that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT07250230Henan Provincial People's HospitalEffect of Perioperative High-dose Transdermal Nicotine Patch on Pain Sensitivity Among Male Abstinent Tobacco Smokers Undergoing Thoracic Surgery: A Randomized Controlled Pilot Study | 2026-12-31 |
| NCT05587361University of OklahomaBeta-Adrenergic Modulation of Drug Cue Reactivity | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies testing Nicotine Patch in Tobacco Use Disorder, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Anxiety sensitivity, reflecting the fear of bodily sensations, is a risk factor for the maintenance and relapse of smoking. This study is designed to address the question - is a smoking cessation intervention personalized to high anxiety sensitive smokers and adapted for implementation by the YMCA effective among racially/ethnically diverse samples?
This protocol provides the recommended treatment to achieve smoking cessation (i.e., counseling and nicotine replacement therapy) and randomly assigns individuals to a high-intensity exercise or low-intensity exercise intervention as a strategy to engage the mechanisms relevant to high anxiety sensitive smokers to improve smoking cessation outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm will be instructed to complete 75 minutes per week of aerobic training at 60-85% of the their heart rate reserve.
Behavioral: Aerobic Exercise · Behavioral: Counseling · Drug: Nicotine patch
Participants assigned to this arm will be instructed to complete 75 minutes per week of aerobic training at 20-40% of the their heart rate reserve.
Behavioral: Aerobic Exercise · Behavioral: Counseling · Drug: Nicotine patch
Participants will select a YMCA branch and will be assigned a personal fitness instructor who will oversee a 15-week exercise intervention. The weekly exercise prescription is 75 minutes of aerobic training.
Participants will receive the standard tobacco cessation package of up to 5 proactive interactions from the Texas Tobacco Quitline (TTQ). Interactions are typically phone calls, but can be chat or live text if the participant prefers. Interaction 1 is for assessment and quit date planning, Interaction 2 occurs prior to the quit date and can be a group session, Interaction 3 occurs shortly following the quit date, and Interactions 4 and 5 are for relapse prevention if the smoker has quit or problem solving if they have not quit. TTQ also offers a tobacco cessation text messaging program and access to a web portal with a variety of cessation resources.
On the target quit day (week 6), participants will be provided 8 weeks of nicotine replacement therapy (24-hour transdermal nicotine patches \[TNP\]).
7-day point prevalence abstinence (PPA) at 6-month follow-up
Self-report of no smoking (not even a puff) during the previous 7 days, verified by expired carbon monoxide (CO; ≤5ppm), saliva cotinine (\<30 ng/mL), or significant other, and not invalidated by any of these verification measures. Failure to provide any of these 3 verification measures will result in PPA being considered missing.
Time frame: Protocol week 30, which is 24 weeks (6 months) after the quit attempt (set at week 6)
7-day point prevalence abstinence (PPA) at 12-month follow-up
Self-report of no smoking (not even a puff) during the previous 7 days, verified by expired carbon monoxide (CO; ≤5ppm), saliva cotinine (\<30 ng/mL), or significant other, and not invalidated by any of these verification measures. Failure to provide any of these 3 verification measures will result in PPA being considered missing.
Time frame: Protocol week 54, which is 48 weeks (12 months) after the quit attempt (set at week 6)
7-day point prevalence abstinence (PPA) at 9-month follow-up
Self-report of no smoking (not even a puff) during the previous 7 days, verified by expired carbon monoxide (CO; ≤5ppm), saliva cotinine (\<30 ng/mL), or significant other, and not invalidated by any of these verification measures. Failure to provide any of these 3 verification measures will result in PPA being considered missing.
Time frame: Protocol week 42, which is 36 weeks (9 months) after the quit attempt (set at week 6)
Plan to share: Yes — Within one year of completion (publication) of the primary aims for this project, we will provide de-identified data from this project to interested researchers. The data are to be provided in a SPSS file or Excel, with separate documentation of labels/characteristics for each column of data. Data will be released directly by Dr. Smits's team at UT to investigators providing evidence of their institution's IRB approval for planned analyses of the data.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Within one year of completion (publication) of the primary aims. No end date.
Access criteria: Data will be released directly by Dr. Smits's team at UT to investigators providing evidence of their institution's IRB approval for planned analyses of the data.
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Mar 2029, 63 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nicotine Patch
Jasper A. Smits